Research, Publications & Presentations

Male Fertility Treatment

Dr. Bastuba has extensive research experience in the areas of male infertility, male sexual dysfunction, vasectomy, vasectomy reversals and urological disorders. A sampling of his research, publications and presentations is listed below:

Research Experience

Sub-Investigator: Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical Study Medication versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients with Multiple Superficial (Ta/T1) Bladder Tumors. Protocol A9601.

Sub-Investigator: A Phase II Study: Intravesical Study Medication in Patients with Carcinoma in Situ of the Bladder Who Have Failed or Have Recurrence Following Treatment with BCG. Protocol A9302.

Sub-Investigator: A Phase II Study: Intravesical Study Medication in Patients with Transitional Cell Carcinoma of the Bladder. Protocol A9303.

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Two Year Group Study of the Efficacy and Safety of Study Medication in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia. Followed by a Two-Year Open Label Treatment Phase Protocol ARIA3001.

Sub-Investigator: A Multi-Center, Open-Label, Dose Escalation Study of the Safety and Therapeutic Effects of Study Medication, Administered as an Intramuscular (IM) or Subcutaneous (SC) Injection, in Prostate Cancer Patients Who Are Candidates for Initial Hormonal Therapy and Prospective Concurrent Control Study. Protocol 149-97-04.

Investigator: A Phase III, Efficacy and Safety Study Comparing Escalating Doses of Study Medication SL to 5mg or 6mg Doses of Study Medication SL or Placebo in the Treatment of Male Erectile Dysfunction. Protocol M97-763.

Investigator: A Phase III, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Study Medication SL Tablets in the Treatment of Male Erectile Dysfunction. Protocol M97-682.

Investigator: A Phase III, Safety and Efficacy Study of Two Fixed Doses of Study Medication SL Tablets versus Placebo in the Treatment of Male Erectile Dysfunction in Patients with Controlled Diabetes. Protocol M97-804.

Sub-Investigator: An Extension Study to Evaluate the Safety and Tolerability of Study Medication in Subjects with Hormone Refractory Adenocarcinoma of the Prostate. Protocol M97-739.

Sub-Investigator: Dose Ranging Study Comparing Best Medical Therapy With and Without Study Medication for the Treatment of Men with Asymptomatic Hormone Refractory Adenocarcinoma of the Prostate. Protocol M96-594.

Sub-Investigator: Dose Ranging Study Comparing Best Medical Therapy With and Without Study Medication for the Treatment of Pain In Men With Symptomatic Hormone Refractory Adenocarcinoma of the Prostate. Protocol M96-500.

Investigator: A Phase III, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Study Medication SL Tablets in a Special Population for the Treatment of Male Erectile Dysfunction. Protocol M97-793.

Sub-Investigator: Study Medication Versus Placebo in the Relief of Stress Incontinence. Protocol F1J-MC-SAAW(c).

Investigator: A Phase II Safety Study of 5mg Study Medication SL Tablets versus Placebo in the Treatment of Patients Diagnosed with male Erectile Dysfunction Following A Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. Protocol M97-788.

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Medication in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia. Protocol ARIB3003.

Sub-Investigator: A Phase III, Multi-Center, Open-Label, Randomized Study of Study Medication vs. Lupron® In Patients with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy. Protocol 149-98-03.

Investigator: A Phase III Efficacy and Safety Study of Three Fixed Doses of Study Medication SL Tablets 2mg and 5mg Versus Placebo in the Treatment of Male Erectile Dysfunction. Protocol M98-941.

Sub-Investigator:: A Multi-Center Study of Study Medication In Patients with Prostate Cancer in Whom GnRH Agonists are Contraindicated. Clinical Study
Protocol No. 149-98-04.

Sub-Investigator: "A Phase III, Open-Label, Multi-Center Study Of The Efficacy And Safety Of Leuprolide Acetate For Depot Suspension 7.5 Mg (30 Day) In Patients With Advanced Prostate Cancer". Protocol OL-002.

Sub-Investigator: Long Term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support. Project #7081 Study # 9901.

Sub-Investigator: Quality of Life (QoL) in Patients Treated with Tolterodine (Detrol) for Overactive Bladder CTN: 583URO0087-070.

Sub-Investigator: A Phase 3, Multi-Center, Open-Label Randomized Study of Study Medication 100 mg IM vs Lupron Deport 7.5mg IM in Patients with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy. Protocol 990744/149-99-03.

Investigator: A 12-Week Safety and Efficacy Study of Oral Study Medication Versus Placebo in Subjects with Overactive Bladder. Protocol No. M98-946.

Sub-Investigator: A Multi-Center, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to that of Ciprofloxacin in the Treatment of Chronic Prostatitis. Protocol CAPSS-101, Phase 3B.

Sub-Investigator: A Rollover, Multi-Center, Open-Label, Maintenance Study of Patients with Prostate Cancer Who were Previously Treated with Study Medication 50 mg or
100 mg IM. Protocol 990789/149-99-04.

Investigator: A Phase 3 Study of the Efficacy of Study Medication (a Protein Kinase C Beta Inhibitor) in Males with Diabetes and Erectile Dysfunction.
Protocol B7A-MC-MBCC.

Sub-Investigator: Phase III Randomized, Double-Blind Study of DMFO vs. Placebo in Low Grade Superficial Bladder Cancer. Protocol DMFO 0341-A2.

Sub-Investigator: A Randomized Clinical Trial Comparing Goserelin Acetate 3.6 mg Depot and Goserelin Acetate 10.8 mg Depot in Subjects with Prostate Cancer for Whom Therapy is Indicated. Protocol 9393IL/0028.

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose, Multi-Center Study to Assess Efficacy and Safety of Daily Oral Administration of Study Medication vs Placebo in Male and Female Subjects with Overactive Bladder. Protocol 905-CL-013.

Investigator: Satisfaction and Experience with Testosterone Replacement Therapy. Protocol UMD-00-067.

Sub-Investigator: Development of a Molecular Classification of Prostate Cancer. Protocol SKCC 9905.

Sub-Investigator: A 12 Week Phase III, Placebo-Controlled Study of Men with Symptomatic BPH. Protocol M99-097.

Sub-Investigator: A Long-Term, Open Label Extension Trial Evaluating the Safety and Efficacy of Study Medication in Subjects with Benign Prostatic Hyperplasia. Protocol M00-179.

Sub-Investigator: A Six-Month, Open Label, Fixed Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of LA-2550 22.5 mg In Patients with Advanced Prostate Cancer. Protocol AGL 9909.

Sub-Investigator: An Eight-Month, Open Label, Fixed Dose Study to Evaluate the Safety, tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of LA2575 30mg in Patients With Advanced Prostate Cancer. Protocol: AGL0001.

Investigator: Prospective, Randomized, Double-Blind, Multi-Center, Comparative Trial to Evaluate The Efficacy and Safety of Ciprofloxacin Once Daily Modefied Release (CIPRO MR) 500mg Tablets for 3 days versus Conventional Ciprofloxacin 250mg Tablets BID for 3 days in The Treatment of Patients With Uncomplicated Urinary Tract (uUTI) Infections. Protocol: 100346.

Sub-Investigator: A Four-Week “Proof of Concept” Study to Determine the Safety, Tolerability and Efficacy of Oral SB 223412 in Patients with Symptoms of Urinary Urgency with or without Incontinence. Protocol: SB223412/020.

Sub-Investigator: A Phase 3B Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of Darfenacin in Subjects with Overactive Bladder. Protocol: A1371047-1221.

Sub-Investigator: Plasma Isolation Study-Fastpack™ PSA Immunoassay. Protocol: SDUC001.

Investigator: Open Label Use of A Unique Testosterone Topical Gel Formulation in Males with an Original Baseline Testosterone Level < 300ng/dl.

Investigator: An Open Label Trial on the Effect of I.V. Zometa 4mg on Bone Mineral. Density in Hormone Sensitive Prostate Cancer Patients. Protocol: CZOL446E US24.

Publications & Preparations

Peer Reviewed Publications

Parrott, T.A. and Bastuba, M.D.: Acute Urinary Retention Secondary to Giant Gladder Diverticulum. British Journal of Urology, May, 1992.

Bastuba, M.D. and Rossmore, H.D.: Microbial Flora of Cutting Fluids. Industrial Microbiology, March 1981.

Bastuba, M.D., Alper, M.M. and Oates, R.D.: Fertility and the Use of Assisted Reproductive Techniques in the Adult Male Exstrophy/Epispadias Patient. Fertility and Sterility, October 1993.

Bastuba, M.D., Saenz de Tejada, I., Dinlenc, C.Z., Sarazen A. Krane, R.J. and Goldstein I.: Arterial Priapism: Diagnosis, Treatment and Long-term Follow-up. Journal of Urology, May, 1994.

Nehra, A.J., Werner, M.A., Bastuba, M.D. Title, C. and Oates R.D.: Vibratory Stimulation and Rectal Probe Electroejaculation as Therapy for Patients With Spinal Cord Injury: Semen Parameters and Pregnancy Rates. Journal of Urology, February 1996.

Gaylis FD, Bastuba M, Bidair M, Friedel WE: Ureteral Dilation Using a Tapered Dilator: A Cost-Effective Approach. Journal of Endourology 14(5): 447-449, June 2000.

Non Peer Reviewed Publications

Impotence in 1996: Pertinent to Your Practice? Absolutely. Grossmont Physician, June 1996.

Advances in Oral Impotence Therapies Signal New Era. Grossmont Physician, April/May 1998.

Presentations

Goldstein, I, Bastuba, M.D.: Impotence and Priapism: Diagnosis and Management. (Post-Graduate instructional Course at American Urological Association Meeting in San Antonio, Texas, May, 1993.)

Bastuba, M.D., Dinlenc, C.Z., Sarazen, A., Greenfield, A., Parker, J. and Goldstein, I.: Long-term Follow up of Patients Treated for High-flow Priapism by Selective Transcatheter Embolization of the Arterial-Lacunar Fistula. (Podium Presentation American Urological Association Meeting in San Antonio, Texas, May, 1993.)

Graham, S.D. and Bastuba, M.D.: Update on AIDS in Urology. Podium Presentation at Southern Medical Association, Urology Section, Atlanta, Georgia, November, 1991.

Bastuba, M.D. and Graham, S.D.: Comparison of MGH-1 and Tumark Antibody Detection in Transitional Cell Carcinoma of the Bladder. Poster Presentation, American Urological Association Meeting, Toronto, Canada, June, 1991.

Bastuba, M.D., Galloway, N.T.M., and Graham, S.D.: G.U. Tumors and AIDS. Podium Presentation, Southeastern Section Meeting, A.U.A., W. Palm Beach, Florida, April 1990.

Internal Medicine Continuing Medical Education Course, Current Trends in Urologic Management. Podium Presentation, CME Associates, San Diego, California, March 21, 1996.

Invited Speaker

Impotence and Infertility: Update 1993. University of California San Diego, University Hospital, San Diego CA, October 15, 1993.

State of the Art Impotence Therapy. Grossmont Hospital La Mesa CA, March 12, 1994.

New Horizons in Infertility. Alvarado Hospital Medical Center, San Diego CA, April 21, 1994.

Impotence and Infertility: Update 1995. University of California San Diego, University Hospital, San Diego CA, August 9, 1995.

Penile Microvascular Revascularization. University of California San Diego, University Hospital, San Diego CA, June 15, 1996.

Management of the Upper Urinary Tract Infection. San Diego State University, Student Health Primary Care Services, San Diego CA, November 9, 1996.

Overcoming Fertility Barriers In the Spinal Cord Injured Male. San Diego Reproductive Endocrine Society, San Diego CA, July 28, 1997.

Infertility: Road to Resolution, San Diego, CA, July 31, 1997

Hematuria and Proteinuria for Primary Care. San Diego State University, Student Health Primary Care Services, San Diego, CA, September 17, 1997.

Evaluating Scrotal Masses & Prostate Nodules, San Diego State University, San Diego, CA, April 15, 1998

Crash Course on Impotence Therapy in the Age of Viagra, Alvarado Hospital Medical Center, San Diego, CA, May 18, 1998

Male Erectile Dysfunction: State of the Art Therapy, Grossmont Hospital, La Mesa, CA, September 15, 1998

What’s Up with Erectile Dysfunction? San Diego Society for Sex Therapy and Education, Sharp Memorial Hospital, San Diego, CA September 25, 1998
Sexual Function in Men with Diabetes & Male Sexuality, Taking Control of Your Diabetes Conference, San Diego Convention Center, San Diego, CA September 19, 1998

Sexual Function & Prostate Cancer: Four Annual Prostate Cancer Public Forum, American Cancer Society, San Diego, CA, October 17-18, 1998

Overcoming Male Factor Fertility Problems: Brody Reproductive Health Institute: You Can Have a Baby Seminar, San Diego, CA, February 6, 1998

Male Sexual Dysfunction: Taking Control of Your Heart Conference, San Diego Convention Center, San Diego, CA, February 13, 1998

Erectile Dysfunction: Asociacion de Medicina General y Familiar de Tijuana, B.C., A.C., February 16, 1999

Treatment of Male Sexual Dysfunction & Penile Implants, Course Director. American Medical Systems, La Jolla, CA, November 7-8, 1999

Overcoming Male Factor Fertility Problems, Brody Reproductive Health Institute, Palm Springs, CA, November 13, 1999

In Preparation

Bastuba, M.D., Sarazen, A. and Oates, R.D.: Transurethral Resection for Treatment of Ejaculatory Duct Obstruction. (Video)

Oates, R.D., Bastuba, M.D., Chiu, A.W. and Babayan, R.K.: Retroperitoneal Vasel Mobilization Utilizing Preperitoneal Laparoscopy. (Submitted to Fertility and Sterility for publication).

Bastuba, M.D. and Oates, R.D.: Phenotypic Expression of Genotypic Variants in Patients with Congenital Bilateral Absence of the Vas Deferens.

Bastuba, M.D. and Oates, R.D.: Phenotypic Expression of Genotypic Variants in Patients with Unilateral Absence of the Vas Deferens.

Bastuba, M.D., Wagner, J. and Oates, R.D.: Varicocele Repair with Local Anesthesia and Intravenous Sedation.